T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dollar General
DG
|
+$1.37B |
| 2 |
Intel
INTC
|
+$1.28B |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$1B |
| 4 |
Nike
NKE
|
+$859M |
| 5 |
Uber
UBER
|
+$825M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.67B |
| 2 |
Amazon
AMZN
|
+$2.15B |
| 3 |
NVIDIA
NVDA
|
+$1.64B |
| 4 |
Humana
HUM
|
+$1.57B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$1.33B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.09% |
| 2 | Healthcare | 15.81% |
| 3 | Financials | 11.13% |
| 4 | Consumer Discretionary | 10.82% |
| 5 | Communication Services | 8.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
W&T Offshore
WTI
$543M
| $76K | ﹤0.01% |
23,222
| – | – |
|
2752
Arbutus Biopharma
ABUS
$898M
| $75K | ﹤0.01% |
29,739
+3,004
| +11% | +$5.88K |
|
2753
Akebia Therapeutics
AKBA
$240M
| $75K | ﹤0.01% |
59,900
| – | – |
|
2754
Advantage Solutions
ADV
$426M
| $74K | ﹤0.01% |
817
+35
| +4% | +$2.49K |
|
2755
Fossil Group
FOSL
$342M
| $74K | ﹤0.01% |
50,388
+18,900
| +60% | +$27.8K |
|
2756
Summit Therapeutics
SMMT
$11.7B
| $74K | ﹤0.01% |
28,006
+1,059
| +4% | +$2.18K |
|
2757
CEL-SCI Corp
CVM
$25.5M
| $73K | ﹤0.01% |
893
| – | – |
|
|
ME
2758
DELISTED
23andMe Holding Co
ME
| $73K | ﹤0.01% |
3,986
+850
| +27% | +$14.7K |
|
2759
Nektar Therapeutics
NKTR
$2.58B
| $71K | ﹤0.01% |
8,317
| – | – |
|
2760
XBiotech
XBIT
$72.3M
| $71K | ﹤0.01% |
17,600
| – | – |
|
2761
SoundHound AI
SOUN
$3.27B
| $70K | ﹤0.01% |
32,617
+1,771
| +6% | +$3.51K |
|
2762
Seer Inc
SEER
$115M
| $67K | ﹤0.01% |
34,139
-1,093,079
| -97% | -$1.94M |
|
2763
Lantronix
LTRX
$275M
| $66K | ﹤0.01% |
11,200
| – | – |
|
|
QVCGA
2764
DELISTED
QVC Group Inc Series A
QVCGA
| $66K | ﹤0.01% |
1,491
-1,604
| -52% | -$55K |
|
|
NXDR
2765
Nextdoor Holdings
NXDR
$1.01B
| $65K | ﹤0.01% |
34,090
+2,488
| +8% | +$4.39K |
|
2766
Workhorse Group
WKHS
$34.6M
| $65K | ﹤0.01% |
60
+30
| +100% | +$35.9K |
|
2767
Rayonier Advanced Materials
RYAM
$573M
| $63K | ﹤0.01% |
15,379
+1,559
| +11% | +$5.13K |
|
2768
Safe Bulkers
SB
$781M
| $63K | ﹤0.01% |
15,816
+441
| +3% | +$1.55K |
|
|
ENZ
2769
DELISTED
Enzo Biochem, Inc.
ENZ
| $63K | ﹤0.01% |
44,800
| – | – |
|
|
OLPX
2770
DELISTED
Olaplex Holdings
OLPX
| $62K | ﹤0.01% |
24,343
+2,901
| +14% | +$5.73K |
|
2771
Quantum Corp
QMCO
$972M
| $62K | ﹤0.01% |
8,760
| – | – |
|
2772
RUM Group Inc
RUM
$3.82B
| $62K | ﹤0.01% |
13,700
| – | – |
|
2773
Sutro Biopharma
STRO
$357M
| $62K | ﹤0.01% |
1,445
+134
| +10% | +$4.25K |
|
2774
Bionano Genomics
BNGO
$13.4M
| $60K | ﹤0.01% |
525
+342
| +187% | +$35.7K |
|
2775
Destination XL Group
DXLG
$33.3M
| $60K | ﹤0.01% |
13,595
+839
| +7% | +$3.59K |
|
Similar funds
T. Rowe Price Associates's Q4 2023 Portfolio in Review
As of Q4 2023, T. Rowe Price Associates held 2,974 positions worth $744B, up 9.1% from $682B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates's Q4 2023 filing shows 92 new, 1,834 increased, 805 reduced and 67 closed positions. Its largest new stake was Canadian Natural Resources: 6,473,658 shares worth $212M. The largest sale was Microsoft, an estimated $2.67B.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q4 2023 buy was Canadian Natural Resources: 6,473,658 shares worth $212M.
- T. Rowe Price Associates added most to Dollar General in Q4 2023, an estimated $1.37B increase.
- T. Rowe Price Associates's biggest Q4 2023 reduction was Microsoft, cutting an estimated $2.67B.
- T. Rowe Price Associates fully exited Activision Blizzard in Q4 2023, selling an estimated $293M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $744B portfolio in Q4 2023.
- T. Rowe Price Associates opened 92 new positions and closed 67 in Q4 2023.
- T. Rowe Price Associates's portfolio value rose 9.1% quarter-over-quarter to $744B.
Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.